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Abstract
Objective To describe weight gain and its variation in smokers who
achieve prolonged abstinence for up to 12 months and who quit without
treatment or use drugs to assist cessation.
Design Meta-analysis.
Data sources We searched the Central Register of Controlled Trials
(CENTRAL) and trials listed in Cochrane reviews of smoking cessation
interventions (nicotine replacement therapy, nicotinic partial agonists,
antidepressants, and exercise) for randomised trials of first line
treatments (nicotine replacement therapy, bupropion, and varenicline)
and exercise that reported weight change.We also searched CENTRAL
for trials of interventions for weight gain after cessation.
Review methods Trials were included if they recorded weight change
from baseline to follow-up in abstinent smokers. We used a random
effects inverse variancemodel to calculate themean and 95% confidence
intervals and the mean of the standard deviation for weight change from
baseline to one, two, three, six, and 12months after quitting. We explored
subgroup differences using random effects meta-regression.
Results 62 studies were included. In untreated quitters, mean weight
gain was 1.12 kg (95% confidence interval 0.76 to 1.47), 2.26 kg (1.98
to 2.54), 2.85 kg (2.42 to 3.28), 4.23 kg (3.69 to 4.77), and 4.67 kg (3.96
to 5.38) at one, two, three, six, and 12 months after quitting, respectively.
Using the means and weighted standard deviations, we calculated that
at 12 months after cessation, 16%, 37%, 34%, and 13% of untreated
quitters lost weight, and gained less than 5 kg, gained 5-10 kg, and
gained more than 10 kg, respectively. Estimates of weight gain were
similar for people using different pharmacotherapies to support cessation.
Estimates were also similar between people especially concerned about
weight gain and those not concerned.
Conclusion Smoking cessation is associated with a mean increase of
4-5 kg in body weight after 12 months of abstinence, and most weight
gain occurs within three months of quitting. Variation in weight change
is large, with about 16% of quitters losing weight and 13% gaining more
than 10 kg.
Introduction
Although smoking cessation results in considerable
improvements in health, it is often accompanied by weight gain.
The link between smoking and body weight has been known
for many years. Cross sectional studies show that, on average,
smokers weigh less than non-smokers, and former smokers
weigh more than both smokers and non-smokers.1 A large
prospective study has shown that adolescents who initiate
smoking gain less weight than their non-smoking peers.2Cohort
studies also show that people who stop smoking gain weight.1 3-8
Smoking cessation probably causes weight gain because nicotine
(in cigarettes) is an appetite suppressant.3 One of the most
common and longlasting symptoms of tobacco withdrawal is
increased appetite.9 Furthermore, evidence suggests that nicotine
increases the basal metabolic rate, and removal of this effect
results in a decline in energy expenditure at a time when appetite
is increased.3
Estimates of the amount of weight that smokers gain when
quitting have varied. A large narrative systematic review1 done
over 20 years ago concluded that weight gain from smoking
cessation was typically 2.9 kg, and this estimate or similar is
often quoted in smoking cessation advice leaflets. However, the
review did not describe the method of combining estimates, and
could have provided an inaccurate estimate of weight gain for
several reasons. Firstly, follow-up periods in the 41 prospective
studies reviewed varied from two weeks to 40 years. Secondly,
measures of both smoking and weight were often self reported,
without validation. Thirdly, the definition of smoking cessation
was often not clear and probably included people who were
“point prevalent” abstinent at the time of follow-up.
Correspondence to: H-J Aubin henri-jean.aubin@pbr.aphp.fr
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e4439 doi: 10.1136/bmj.e4439 (Published 10 July 2012) Page 1 of 21
Research
RESEARCH
People who meet the definition of point prevalence abstinence
will include those who have been continuously or intermittently
abstinent for years, or those who have recently stopped only
days or weeks before measurement. Point prevalence abstinence
was more likely to have been used in the population based
studies included in this review, such as the Framingham study,10
because participants were not given a target quit date and
followed from that point. A previous study has shown that the
mean weight gain in studies measuring point prevalence
abstinence was lower than those measuring weight change in
continuous abstainers.11
We aimed to describe weight changes seen in smokers who
were motivated to quit. Data in this study were derived from
clinical trials of first line smoking cessation drugs and from
trials of interventions designed to limit weight gain after
cessation. We previously published a Cochrane review that
examined the effectiveness of these interventions on preventing
such weight gain in the short term and at six and 12 month
follow-up in full detail.12 The three treatments commonly used
around the world are nicotine replacement therapy, bupropion,
and varenicline. In brief, the Cochrane review showed that all
three treatments reduced weight gain by 0.5 kg (nicotine
replacement therapy), 1.1 kg (bupropion), and 0.4 kg
(varenicline). There was no evidence that any of them reduced
weight gain at one year, but the data were too imprecise to
exclude effects of similar size. In the present study, rather than
describing the effect of treatment on limiting weight gain, we
described the weight change over time, and its variability
between individuals for smokers who quit using these
treatments, and for those who quit without using them, during
the first 12 months of abstinence.
Methods
The aim of this study was to estimate the mean weight change,
and the variation around the mean of that change, in smokers
who presented for smoking cessation treatment and achieve
abstinence. Most data were derived from clinical trials of first
line interventions for smoking cessation, published in Cochrane
reviews. The primary aim of most of the reviewed trials was to
assess the effectiveness of the pharmacological interventions
to assist quitting. These data and adverse event data were
summarised in the relevant Cochrane reviews.13-17We used these
trials to estimate mean weight change and its variation in
untreated quitters (control arm data) and treated quitters
(treatment arm data).
A second group of trials examined the effectiveness of specific
interventions to prevent weight gain after cessation. Such trials
typically enrolled smokers especially concerned about gaining
weight and randomised them to standard support for smoking
cessation or standard support plus an intervention to prevent
weight gain. Here, we used data from the control groups only
because some of these interventions were effective in reducing
weight gain.12 We used these data to estimate weight change in
weight concerned smokers, because some authors have shown
increased weight gain in this group.18
A third group of studies examined the effectiveness of exercise
in promoting smoking cessation. A systematic review of
randomised trials showed convincing evidence indicating that
exercise suppresses cravings to smoke. Most trials of exercise
in the Cochrane review on the effect of exercise on cessation
did not report data for weight gain nor appeal to weight
concerned smokers.17Nevertheless, exercise could reduceweight
gain,12 and we included only the control arms of these trials to
estimate weight change in untreated quitters.
Search strategy and study selection
Trials included in this study were identified from our Cochrane
review on interventions to prevent weight gain.12 The search
was updated in November 2011, and is reported in detail
elsewhere. In brief, we searched the included lists of Cochrane
reviews of smoking cessation interventions—nicotine
replacement therapy (last search date, October 2007),15
antidepressants (July 2009),16 nicotine receptor partial agonists
(October 2010),13 and exercise interventions (July
2011)17—published in version 11 of the 2011 Cochrane Library.
We updated the searches for nicotine replacement therapy,
bupropion, varenicline, and exercise trials published since the
last search date for each Cochrane review to November 2011
by searching the Cochrane CENTRAL register (Central Register
of Controlled Trials) using a combination of smoking and
treatment search terms. In addition, we searched the Cochrane
Tobacco Addiction Group specialist register for interventions
that specifically targeted weight gain after cessation in addition
to smoking cessation (search date, November 2011), using a
combination of smoking and weight related search terms.
For inclusion in our review, studies had to report or their authors
had to supply data for weight change from baseline to at least
one follow-up point in abstainers only. Almost all studies of
nicotine replacement therapy, varenicline, bupropion, and
exercise did not report weight data in either the title or abstract.
Consequently, we assessed the full text of every study in the
latest versions of the reviews of effectiveness of the four
treatments for inclusion. For the update search, we obtained and
read the full text of every trial, if the title or abstract made it
apparent that it was a trial of one of these interventions. We
contacted authors or sponsors (or both) if weight data were
incompletely recorded or missing but it was clear that
participants had been weighed. Likewise, we screened the full
text of any trial in which the title or abstract clearly indicated
that the intervention aimed to allay concern about weight gain
after cessation or aimed to prevent such weight gain. Studies in
foreign languages were translated into English.
Data extraction
Three authors (H-JA, AF, DL) extracted data, with each study
having data extracted by two independent authors. Remaining
differences were resolved by a fourth author (PA) extracting
data and thereafter by consensus.We extracted the mean weight
change (kg), standard deviation, and number of participants
contributing to the mean from baseline to each given time point,
in abstinent smokers only. Time points were calculated in
reference to the target quit date. Time points were aggregated
into months (weeks two to five=month one; weeks six to
nine=month two; weeks 10-13=month three; weeks
22-26=month six; weeks 50-56=month 12.
Study quality assessment
Although the data were derived from randomised controlled
trials, weight gain was not considered by randomisation group,
and therefore we treated the data as observational. As such, we
based our assessment of quality on the framework proposed by
Altman, a widely cited framework tailored to the assessment of
descriptive cohort studies.19 Study quality was mainly based on
the assessment of smoking status and weight (table 1⇓). We
assessed whether studies reported smoking abstinence as
prolonged or continuous—that is, whether participants had
sufficient time for weight gain to occur, or had point prevalence
abstinence. In addition, a proportion of patients treated in clinics
can claim abstinence even if they have not achieved it.
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Biochemical validation would reduce the number of people
falsely claiming abstinence, which would underestimate weight
gain if such participants were included; therefore, we also
extracted data regarding the use of biochemical validation.
Finally, we examined whether studies reported howweight was
assessed, and we categorised studies that obtained self reported
weights, which are known to be subject to error,20 from those
studies in which people were weighed.
Data analysis
We combined data to describe weight change in quitters treated
with varenicline, bupropion, or nicotine replacement therapy,
and in those who were not given these treatments (“untreated
quitters”). To estimate weight change in the untreated quitters,
we combined data from the control group of trials of nicotine
replacement therapy, varenicline, bupropion, and exercise for
smoking cessation, and from the control group of trials of
interventions to prevent or allay concerns about weight gain
after cessation. Treated quitter groups included data from the
active treatment arm of trials of nicotine replacement therapy,
varenicline, and bupropion. We kept these groups separate
because these pharmacotherapies could have a small effect on
weight gain in the short term.12 We combined studies with
multiple treatment arms of the same pharmacotherapy (that is,
testing different dose regimens or preparations). Control groups
in which participants received one form of pharmacotherapy
were not included in the meta-analysis for untreated quitters,
but rather in the corresponding treatment group. We excluded
treatment groups that received more than one pharmacotherapy.
We used a random effects inverse variance model to estimate
a summary mean for weight change and 95% confidence
intervals at months one, two, three, six, and 12 for each of the
groups described above. The random effects model was chosen
because of the high heterogeneity between trial estimates in
each meta-analysis. The underlying assumption of a random
effects model is that the true effect could vary between studies,
based on characteristics of the study population or intervention.
In this case, for example, the population mean might differ if
participants are younger; healthier, by baseline bodymass index
or previous quit history; or if the study used a more intensive
or longer intervention.
The studies in the meta-analysis were assumed to be a random
sample of the relevant distribution of effects, and the combined
effect estimated the mean effect of these different subpopulation
means. We measured heterogeneity using the I2 statistic. We
also estimated the variation in weight change by calculating a
weighted mean (according to the number participants in the
study) of the standard deviations. Using z scores, we calculated
the percentage of the quitting population whowould be expected
to lose weight, remain stable, gain less than 5 kg, gain 5-10 kg,
or gain more than 10 kg over 12 months. We assumed that
weight change after cessation is roughly normally distributed.
We believe this assumption is reasonable; data from our trials
suggest weight gain after cessation is normally distributed.21 22
Also, other trials have reported means and standard deviations
rather than medians and interquartile ranges, which they might
have reported if data were skewed. We did all analyses using
the Comprehensive Meta Analysis statistical program (version
2.2.50) and Stata (version 10).
Subgroup analyses
Owing to the heterogeneity present, we sought to identify
subgroups with differing mean weight gain. We combined data
from all studies at 12 month follow-up, using a random effects
metaregressionmodel with a binary predictor variable for weight
concern. Twelve month data were used, because any effect of
treatment on weight has not been shown to persist beyond this
follow-up point.12
Sensitivity analyses
We evaluated the effect of study quality criteria on estimates
of weight change in data from all studies combined at 12 month
follow-up, using a random effects meta-regression model. We
used binary predictor variables to assess whether the mean
weight change differed in studies defining abstinence as point
prevalence abstinence versus prolonged or continuous
abstinence, and whether weight was measured at the clinic or
elsewhere, at each follow-up point. It was not possible to test
the effect of biochemical confirmation of abstinence, because
all but one study confirmed abstinence biochemically.
Publication bias
Most trials assessed did not report weight gain, and it is possible
that trials chose to report weight gain only if the gain was
remarkably high. We constructed funnel plots for weight
estimates for untreated patients and patients treated with nicotine
replacement therapy, bupropion, and varenicline at three and
12 months to test for plot symmetry, in order to detect any
publication bias.
Results
Included studies
Of 212 trials in the Cochrane reviews of nicotine replacement
therapy, varenicline, bupropion, and exercise, 53 recorded
weight change at one or more follow-ups (fig 1⇓).We also found
another trial with weight data in the updated search. Of these
54 trials, three were excluded because all groups received some
intervention that could affect weight gain. The search of online
databases for studies aimed at preventing weight gain after
cessation led to the full text search of 16 studies. Of these, 11
were included and an additional two were already found from
searches of the Cochrane reviews. The three excluded trials all
offered interventions that might limit weight gain to all
participants. In total, we included 62 trials.
Description of studies and quality assessment
Studies often had eligible data from more than one trial arm
(control and treatment arms), and some studies contributed data
for more than one treatment. In total, 51 studies contributed
weight change data in participants under control conditions
(untreated quitters). Nine of these studies tested interventions
to limit weight gain and largely recruited weight concerned
smokers.21 23-30 Data for weight gain in smokers taking nicotine
replacement therapy (any preparation, any strength), bupropion
(300 mg/day), and varenicline (2 mg/day) were collected from
34, 10, and 12 studies, respectively. Of the 62 included trials,
59 enrolled populations from North America, Europe, or
Australia, and the remaining three31-33 were conducted in east
Asian countries (table 2⇓). One study30 reported weight change
at months three, six, and nine. Since this study was the only one
with a nine month time point, we did not include the data at
nine months. We could not extract data for weight gain by sex,
because it was not presented in any study. Seven studies
recruited women only.23 25 29 30 35 36 86 One of these studies
investigated exercise, and the remaining trials analysed
interventions for weight gain after cessation. All other trials
recruited both men and women.
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Overall, studies were of high quality. Fifty one studies measured
weight change in abstinent smokers, using the definition of
prolonged abstinence or continuous abstinence from the first
day of quitting. All but one of these studies validated abstinence
biochemically.37 Two other studies had definitions similar to
the Russell standard criterion for prolonged abstinence and we
counted them as such.38 One study allowed participants to “slip
up” for up to seven consecutive days,39 and another40 allowed
patients to have up to three cigarettes per week but verified them
as abstinent by carbon monoxide measurement. Eight
studies23 24 41-45 defined abstinence as biochemically validated
point prevalence at seven days. One study46 did not define
abstinence.
Two studies used self reported weight37 47 and 33 reported (or
authors or sponsors confirmed) weighing participants. Twenty
six studies did not report whether participants were weighed or
data were self reported.We recorded weight assessment in these
studies as unclear, although all studies but one46 biochemically
validated abstainers at follow-up (and therefore must have had
a face-to-face meeting) and therefore probably measured
participants’ weight rather than using participants’ self reported
weight. No studies reported details of weight measurement such
as validated scales or clothing requirements.
Effect on weight gain
Table 3⇓ and figures 2-8⇓⇓⇓⇓⇓⇓⇓ shows the means and 95%
confidence intervals for weight change from baseline in treated
and untreated smokers during the first 12 months of abstinence.
In all groups, weight increased by about 1 kg per month for the
first three months. Thereafter, the rate of increase reduced,
leading to an estimated weight increase of about 4-5 kg at one
year after cessation.
There were small differences in the estimates between different
pharmacotherapies.We did not test for the significance of these
differences because these data were available in the Cochrane
review.12 Table 3 shows weighted mean standard deviations,
which indicated a large variation between participants. Using
z scores, we calculated the percentage of the quitting population
who would be expected to lose weight, remain stable, gain less
than 5 kg, gain 5-10 kg, or gain more than 10 kg over 12months
(figs 9-11⇓⇓⇓). At 12months, 16-21% of untreated participants
lost weight, 35-38% gained less than 5 kg, 29-34% gained 5-10
kg, and 13-14% of participants gained more than 10 kg. These
proportions were similar for participants who had used first line
treatment for smoking cessation.
Subgroup analyses
We found no clear difference between the mean weight gain in
studies that treated weight concerned smokers and those that
treated the general population of smokers (table 4⇓). Therefore,
the findings reported above and in table 3 include all data
regardless of study participant selection for weight concern.
Sensitivity analyses and publication bias
Weight gain at 12 months was lower in trials that recorded
abstinence as point prevalence, than in those that measured
weight in prolonged or continuous abstainers, although this
difference was not significant (3.80 kg (95% confidence interval
2.31 to 5.29) v 4.74 kg (4.33 to 5.16), P=0.14). We found no
significant difference at all time points in weight gain between
trials that measured weight at the clinic or when weight was
reported otherwise. All studies reporting weight data at 12
months biochemically confirmed abstinence; therefore,
sensitivity analysis by this study quality variable was not
performed. No funnel plot showed evidence of asymmetry,
providing good evidence that the trials represent a random
selection of weight change estimates. Plots are available on
request from the authors.
Discussion
Our meta-analysis has shown that abstinent smokers gain a
mean weight of 4-5 kg after 12 months of abstinence. However,
we have found substantial variation in weight gain, indicating
that this mean value does not reflect many people who give up
smoking. We estimated that at 12 months, 16-21% of
participants lost weight and 13-14% gained more than 10 kg.
Although weight gain after smoking cessation is widely
recognised, this meta-analysis provides clinicians and patients
with a more robust and detailed description of the first 12
months of weight change after cessation. The finding of a mean
weight gain of 4.7 kg in untreated quitters at one year after
smoking cessation is substantially higher than the 2.9 kg often
quoted in smoking cessation advice leaflets, which stemmed
from a previous review.1 Moreover, this mean weight gain is
greater than the 2.3 kg gain that female smokers report being
willing to tolerate, on average, before embarking on a quit
attempt.48
This review reports on variation in weight gain, which is rarely
described or discussed in the literature, and has clinical
implications. Some people are either destined or able to prevent
weight gain without intervention, whereas others seem likely
to gain enough weight that puts them at increased risk of
diabetes, among other complications.49 In practice, doctors could
detect people gaining excessive weight and intervene early to
prevent this.
Wewere unable to show a significant difference between weight
change estimates in point prevalence abstainers and prolonged
or continuous abstainers, and therefore, we combined all
estimates at each time point regardless of abstinence definition.
This may be because the data were derived from clinical trials,
in which participants were all given the same target quit date,
and therefore many point prevalence abstainers were also
prolonged abstainers.50However, the point estimate did indicate
a smaller weight change in point prevalence abstainers and it is
possible that this difference was the case in our analysis,
although it was not sufficiently powered to detect statistical
significance.
Most trials aimed at preventing weight gain typically enrolled
weight concerned women, but did not provide clear evidence
that this group were at risk of greater weight gain. This result
might seem surprising, since people concerned about weight
may have experienced excessive weight gain in previous quit
attempts, and excessive gain is associated with greater weight
gain in a current quit attempt.51 However, the association
between weight concerns and weight gain after cessation is
unclear.18 52 53 Furthermore, nearly all such trials recruited
exclusively women, whereas trials appealing to the general
population were all mixed sex. Consequently, the data were
inevitably confounded and also not precise enough to exclude
a difference between weight concerned populations and
populations not specifically concerned about weight gain.
Our estimates provided the difference between starting weight
and weight up to one year later. Themeanweight of a population
is likely to increase over one year independently of a smoking
cessation attempt.54 The Lung Health Study showed that
continuing smokers gain on average of 0.3 kg/year for men and
0.5 kg/year for women.55 Another study7 estimated a gain of
about 0.3 kg/year for both sexes, meaning that roughly 4.3 kg
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of the mean weight gain at 12 months in our analysis was due
to cessation (table 3).
These data relate only to weight gain in people who achieve
and maintain abstinence, but provide no evidence on what
happens to weight in smokers who are abstinent and then relapse
or in continuing smokers who never achieve abstinence. For
smokers who gain weight on cessation, available data suggest
that they lose weight again if they relapse to smoking,56 although
few studies have reported data for weight gain in those who
relapse. An incremental weight gain would be important because
many people repeatedly attempt to quit. Furthermore, because
few trials followed participants beyond one year, we cannot
report here on weight gain beyond this time point. Evidence is
conflicting as to whether weight continues to increase beyond
the first year after cessation.55 57-59
We limited our review to randomised controlled trials for
smoking cessation, pharmacotherapy use, exercise, and
interventions aiming to prevent weight gain. The validity of
data for weight gain after cessation depends on accurate timing
of the start of abstinence, the validity of recording of abstinence,
and frequent follow-up. Most of the trials we reviewed show
these features but few observational studies do.We also limited
our review to trials in the Cochrane reviews of first line
treatment, which led to the exclusion of a few other trials, chiefly
the Lung Health Study.55 However, estimates of the effect of
cessation on weight gain at one year from the LungHealth Study
were similar to our estimates, and there was no reason to
presume that using data from only randomised controlled trials
created a bias.
Limitations
These data were derived from smokers treated in clinics for
tobacco dependence. Such groups are usually more dependent
and heavier smokers than the general population of smokers.
There is conflicting evidence that heaviness of smoking relates
to weight gain,4 with different studies reporting that heavier
smokers gain more weight, or that moderate smokers gain most
weight. Smokers seeking treatment could differ from those who
quit on their own in other ways. Most people do not attend
smoking cessation clinics or consult their doctor for help until
they have tried and failed to stop smoking themselves. Their
previous failure to accomplish one goal, smoking cessation,
could reflect on their ability to limit weight gain after cessation.
This theory is speculative, however. The differences between
the population enrolled in clinical treatment and smokers quitting
without clinical help could be related to weight gain after
cessation. A systematic review of population based studies,
taking careful account of the assessment of continuing
abstinence, would be needed to assess weight gain after smoking
cessation in the general population. Therefore, our review data
are directly relevant to clinicians who only treat smokers who
present for help with cessation.
Weight gain was reported in only 25% of the smoking cessation
trials considered for inclusion. It was not possible to determine
whether those studies reporting weight were a biased sample of
all smoking cessation trials, although we found no evidence of
bias on the funnel plot. Trials that aimed to prevent weight gain
after cessation reported weight change as a primary outcome,
and we observed no difference in weight gain between these
trials and the treatment trials, in which only a minority reported
weight gain.
Different studies, and therefore different study participants,
contributed data to the meta-analyses at each time point and we
noted heterogeneity in most analyses. We therefore cannot
interpret mean weight change across different time points as a
trajectory. Studies would need to report individual weight gain
trajectories, rather than cross sectional means, for us to
summarise these changes. Large weight gain might lead to
intentional relapse to smoking, which would mean that people
who put on large amounts of weight early in their quit attempt
and relapse were not represented by our data. However, data
are conflicting for the association between weight gain and
probability of relapse.51 60-68
Conclusions
Previous reports have underestimated the average amount of
weight gained when people stop smoking. In clinic treated
smokers, the population mean is about 4-5 kg after 1 year.
Weight gain is greatest during the first three months of quitting
(average monthly weight gain of about 1 kg), after which the
rate of increase declines. However, we saw a large variation
around the population mean. At 12 months, about 16-21% of
participants lost weight and 13-14% gained more than 10 kg.
Weight gain is important because weight concern is widespread
among smokers and could deter some from trying to quit.
Gaining weight after cessation limits some of the health benefits
of quitting and is associated with an increased risk of health
problems.69-73 So far, interventions have had a limited effect on
preventing weight gain.12 These data suggest that doctors might
usefully give patients a range of expected weight gain, although
further research should identify the subgroups most at risk of
gaining weight and clarify the optimum content and timing of
interventions to prevent weight gain after cessation.
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Tables
Table 1| Application of Altman’s criteria for judging the quality of studies on outcome
How applied in this reviewAltman criteriaCriterion
All cohorts included smokers wanting to quit, assembled before
quit day and with time measured from quit day. Population
categorised by type of abstinence measure (that is, prolonged or
continuous, point prevalence and biochemically confirmed or not).
Inclusion criteria defined, sample selection explained, adequate
description of diagnostic criteria, clinical and demographic
characteristics fully described, representative, assembled at
common (usually early) point in course of disease, complete (all
eligible patients included)
Sample of patients
Followed at 1, 2, 3, 6, and 12 monthsSufficiently longFollow-up of patients
Self reported weight, measured weight, presumed measured, and
unclear
Objective, unbiased (for example, assessment blinded to
prognostic information), fully defined, appropriate, known for all
or high proportion of patients
Outcome
Not applicable. The aim of the study was not to assess the effect
of a particular prognostic factor but to record the outcome in all
who were abstinent
Continuous predictor variable analysed appropriately, statistical
adjustment for all important prognostic factors
Analysis
Recorded pharmacological treatment received or no active
treatment to prevent weight gain
Fully described, treatment standardised or randomisedTreatment subsequent to
inclusion in cohort
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Table 2| Study description and quality variables
Mean smoking
intake at
Mean
age at
Women
atPatients
(no) at
baselineTreatment*
Weight
measurement
Biochemical
validationAbstinenceRegion
Weight
change
follow-up
points
Aim of
treatmentTrial
baseline
(cigarettes/day)
baseline
(years)
baseline
(%)
28 (10)41 (10)4299NRTNRYesPAEuropeMonth 3SCAbelin et al
198940
27 (11)43 (11)72100Control
2343 (11)52376VareniclineClinic
weighed
YesPAEuropeMonth 3SCAubin et al
200874
2243 (12)50370NRT
29 (1)4271240NRTNRYesCAEuropeMonths 6,
12
SCBlondal et al
199975
25 (10)37 (9)51400NRTNRYesPAEuropeMonths 6,
12
SCBohadana et
al 200076
23 (8)38 (11)100148NRTClinic
weighed
YesPPUSAMonths
2, 6, 12
SC and
PCWGP
Cooper et al
200523
23 (8)39 (10)100148Control
26 (11)†48 (12)†5652NRTClinic weighedYesCAUSAMonths 2,
12
SCDale et al
199577
22 (7)NRNR56NRTClinic
weighed
NRNREuropeMonth 2SCEhrsam et al
199146
24 (7)NRNR56Control
28 (8)43 (10)5744NRTNRYesPPUSAMonth 2SCFiore et al
1994a41
30 (10)43 (9)5643Control
30 (10)43 (9)6857NRTNRYesPPUSAMonth 2SCFiore et al
1994b41
31 (10)44 (11)6755Control
24 (11)41 (12)49405NRTClinic
weighed
YesPAUSAMonth 1SCGarvey et al
200039
23 (11)40 (12)51203Control
21 (10)43 (12)40352VareniclineClinic
weighed
YesPAUSAMonth 3SCGonzales et
al 200678
21 (9)42 (12)42329Bupropion
22 (10)43 (12)45344Control
28 (10)41 (11)58315NRTNRYesCAAustraliaMonth 3SCGourlay et al
199579
27 (9)42 (10)57314Control
33 (11)42 (10)51132NRTClinic
weighed
YesCAUSAMonth 3SCGross et al
199580
46Control
32 (12)39 (9)2754ControlClinic weighedYesPPUSAMonths 2,
12
SC and
PCWGP
Hall et al
199224
24 (10)43 (11)46106NRTNRYesCAEuropeMonth 6SCHjalmarson
et al 198481
24 (10)41 (14)56100Control
21 (6)45 (12)42125NRTClinic
weighed
YesCAEuropeMonth 12SCHjalmarson
et al 199482
22 (8)45 (12)57123Control
22 (8)48 (11)38123NRTNRYesCAEuropeMonths
1, 2, 3, 6,
12
SCHjalmarson
et al 199783
21 (8)47 (10)64124Control
27 (11)45 (12)51156BupropionNRYesCAUSAMonths
2, 6, 12
SCHurt et al
199784
27 (9)43 (11)55153Control
23 (10)45 (11)45344VareniclineNRYesCAUSAMonth 3SCJorenby et al
200685
22 (9)43 (12)40342Bupropion
22 (9)42 (12)41341Control
22 (10)†28 (8)†10020ControlNRYesCAUSAMonth 1SC and
PCWGP
Klesges et al
199086
NRNRNR55ControlClinic weighedYesCAUSAMonth 1SC and
PCWGP
Klesges et al
199534
21 (11)46 (11)54299NRTSelf reportedNoCAUSAMonths 2,
6
SCLerman et al
200437
20 (7)41 (11)10089BupropionClinic
weighed
YesPAUSAMonths
3, 6, 12
SC and
PCWGP
Levine et al
201025
22 (9)42 (10)10067Control
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Table 2 (continued)
Mean smoking
intake at
baseline
(cigarettes/day)
Mean
age at
baseline
(years)
Women
at
baseline
(%)
Patients
(no) at
baselineTreatment*
Weight
measurement
Biochemical
validationAbstinenceRegion
Weight
change
follow-up
points
Aim of
treatmentTrial
22 (9)40 (9)100147ControlClinic weighedYesCAUSAMonths 3,
12
SCMarcus et al
199935
24 (10)40 (12)21130VareniclineClinic
weighed
YesPAAsiaMonth 3SCNakamura et
al 200731
23 (9)40 (12)24129Control
27 (11)41 (10)61333ControlClinic weighedYesCAUSAMonth 2SCNiaura et al
200287
2242 (11)50157VareniclineClinic
weighed
YesPAUSAMonth 3SCNiaura et al
200888
2242 (12)47155Control
19 (7)42 (11)50127VareniclineClinic
weighed
YesPAUSAMonth 2SCNides et al
200689
20 (7)41 (11)55128Bupropion
22 (8)42 (10)51123Control
20396573ControlClinic weighedYesCAEuropeMonths 2,
3, 6, 12
SC and
PCWGP
Norregaard et
al 199626
27 (11)46 (11)4693ControlClinic weighedYesCAUSAMonth 2SC and
PCWGP
O’Malley et al
200627
21 (9)43 (10)51259VareniclineClinic
weighed
YesPAUSAMonth 2SCOncken et al
200690
20 (7)43 (9)48129Control
23 (10)43 (12)56408NRTNRYesPPUSAMonth 2,
6, 12
SCPack et al
200842
22 (12)49 (13)7135ControlClinic weighedYesPAEuropeMonths 1,
6
SC and
PCWGP
Parsons et al
200921
26 (5)46 (10)10075ControlClinic weighedYesCAUSAMonths 1,
6, 12
SC and
PCWGP
Perkins et al
200128
23 (11)42 (11)60224BupropionClinic
weighed
YesPPUSAMonth 2SCPiper et al
200743
22 (10)42 (11)60156Control
27 (12)42 (9)100108NRTClinic
weighed
YesCAUSAMonths
1, 6, 12
SC and
PCWGP
Pirie et al
199229
26 (12)42 (9)100103Control
21 (9)40 (9)43300NRTNRYesPAEuropeMonths 6,
12
SCPuska et al
199591
NRNRNR153NRTNRYesPAAustraliaMonths
3, 6, 12
SCRichmond et
al 199492
NRNRNR152Control
23 (14)57 (10)31124BupropionNRYesPPUSAMonths
3, 12
SCRigotti et al
200644
21 (11)55 (10)31124Control
2257 (9)25355VareniclineClinic
weighed
YesCAWorldwideMonths
3, 12
SCRigotti et al
201093
2356 (8)18359Control
27 (9)48 (11)59113NRTNRYesCAUSAMonth 6SCSachs et al
199394
29 (11)48 (11)59107Control
NR415248NRTNRYesCAUSAMonth 6SCSaules et al
200495
18 (8)41 (12)57459NRTClinic
weighed
YesCAUSA EuropeMonths
3, 6, 12
SCShiffman et
al 2002a96
17 (9)40 (12)60458Control
26 (11)44 (12)57450NRTClinic
weighed
YesCAUSA-EuropeMonths
3, 6, 12
SCShiffman et
al 2002b96
27 (10)45 (12)53451Control
23 (11)49 (11)16123NRTUnclearYesCAUSAMonth 12SCSimon et al
200497
16 (11)55 (8)742BupropionNRYesCAUSAMonth 6,
12
SCSimon et al
200998
16 (9)57 (7)043Control
27 (12)41 (11)10048ControlClinic weighedYesPAUSAMonth 3SC and
PCWGP
Spring et al
199536
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Table 2 (continued)
Mean smoking
intake at
baseline
(cigarettes/day)
Mean
age at
baseline
(years)
Women
at
baseline
(%)
Patients
(no) at
baselineTreatment*
Weight
measurement
Biochemical
validationAbstinenceRegion
Weight
change
follow-up
points
Aim of
treatmentTrial
20 (9)43 (11)100107ControlClinic weighedYesPAUSAMonths 3,
6
SC and
PCWGP
Spring et al
200430
24 (7)40 (10)58800NRTNRYesCAEuropeMonths
3, 12
SCStapleton et
al 199599
24 (8)42 (10)55400Control
25 (10)39 (9)63116NRTClinic
weighed
YesPAEuropeMonth 12SCSutherland
et al 1992100
27 (10)40 (10)66111Control
25 (11)57 (9)37248VareniclineNRYesPAUSA-EuropeMonths
3, 12
SCTashkin et al
2011101
2457 (9)38251Control
22 (9)46 (11)7285NRTClinic weighedYesPPUSAMonths 1,
6
SC and
PCWGP
Toll et al
201045
214569145NRTNRYesPAEuropeMonths
3, 12
SCTonnesen et
al 1991102
224570144Control
20 (6)39 (12)63145NRTNRYesPAEuropeMonths
3, 12
SCTonnesen et
al 1993103
20 (7)39 (14)60141Control
27 (10)41 (10)512861NRTNRYesCAEuropeMonths
2, 6, 12
SCTonnesen et
al 1999104
27 (10)41 (10)48714Control
22 (8)44 (11)511927VareniclineClinic weighedYesCAUSA-Canada-EuropeMonth 6SCTonstad et al
2006105
31 (10)42 (10)70664NRTNRYesCAUSAMonth 2SCTransdermal
Nicotine
Study Group
1991106
31 (11)43 (10)60271Control
2340 (9)19126VareniclineClinic
weighed
YesPAAsiaMonth 3SCTsai et al
200732
2341 (11)7124Control
NR36 (11)1250BupropionSelf-reportedYesCAEuropeMonth 6SCUyar et al
200747
NR36 (13)2050NRT
NR36 (11)3031Control
18 (5)45 (12)63123NRTNRYesCAEuropeMonth 12SCWallstrom et
al 2000107
21 (7)45 (11)59124Control
20394165VareniclineClinic
weighed
YesPAAsiaMonths
3, 12
SCWang et al
200933
21393168Control
22 (8)40 (9)64517BupropionNRYesPAEuropeMonths
2, 12
SCZellweger et
al 2005108
24 (9)40 (9)64170Control
SC=smoking cessation; PCWGP=postcessation weight gain; NRT=nicotine replacement therapy; NR=not reported; PA=prolonged abstinence; CA=continuous abstinence;
PP=point prevalence abstinence. For the Shiffman studies, smokers were stratified and received two different treatments on the basis of nicotine dependence level
(separated in “a” and “b” groups). For the Fiore studies, “a” and “b” refer to two separate studies reported in the same article.
*Control=data taken from placebo arms of pharmacotherapy trials and control arms of behavioural interventions. Only included if participants did not receive any
intervention that could have affected weight (for example, nicotinic replacement therapy, exercise, dietary advice).
†Whole study population analysed.
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Table 3| Meta-analysis of combined data for weight change from baseline, by treated and untreated quitter groups
No of studiesNo of participantsI2 (%)
Weighted mean
standard deviation†
Mean (95% CI) change in weight
(kg)*
Time after target quit day
Untreated quitters (weight concerned and non-weight concerned)
6135571.411.12 (0.76 to 1.47)Month 1
16556641.942.26 (1.98 to 2.54)Month 2
25776842.792.85 (2.42 to 3.28)Month 3
18409524.214.23 (3.69 to 4.77)Month 6
25514694.724.67 (3.96 to 5.38)Month 12
Quitters treated with nicotine replacement therapy
4257511.650.96 (0.70 to 1.23)Month 1
101174652.642.00 (1.72 to 2.27)Month 2
11899932.522.29 (1.68 to 2.89)Month 3
171121764.043.65 (3.17 to 4.12)Month 6
191138714.534.86 (4.34 to 5.38)Month 12
Quitters treated with bupropion (300 mg/day)
Not determinedNot determinedNot determinedNot determinedNot determinedMonth 1
437702.631.36 (1.16 to 1.56)Month 2
4244772.872.31 (1.42 to 3.21)Month 3
448615.702.71 (0.84 to 4.59)Month 6
518304.864.08 (3.44 to 4.71)Month 12
Quitters treated with varenicline (2 mg/day)
Not determinedNot determinedNot determinedNot determinedNot determinedMonth 1
212703.512.19 (1.62 to 2.77)Month 2
91052812.672.12 (1.74 to 2.50)Month 3
130103.304.03 (3.66 to 4.40)Month 6
3174915.314.17 (1.64 to 6.71)Month 12
*Calculated from random effects meta-analysis, which assumes that there are several different underlying true values for weight change, depending on population.
†Mean of the standard deviations for each study contributing data to time point mean, weighted by the number of participants contributing data to each mean. This
value gives the standard deviation in weight gain for all participants within the study populations as a whole.
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Table 4| Subgroup analyses for untreated quitters, by time point
PNo of studiesI2 (%)Mean (95% CI)
1 months after cessation
0.04200.81 (0.61 to 1.02)Weight concerned
401.46 (1.08 to 1.84)Not selected for weight concern
2 months after cessation
0.013261.58 (1.21 to 1.96)Weight concerned
13242.46 (2.25 to 2.69)Not selected for weight concern
3 months after cessation
0.385543.24 (2.51 to 3.98)Weight concerned
20832.77 (2.29 to 3.24)Not selected for weight concern
6 months after cessation
0.147554.71 (3.47 to 5.95)Weight concerned
11514.06 (3.49 to 4.65)Not selected for weight concern
12 months after cessation
0.966504.22 (2.71 to 5.73)Weight concerned
19734.79 (3.98 to 5.60)Not selected for weight concern
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Figures
Fig 1 Study selection for inclusion in meta-analysis
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Fig 2 Meta-analyses of mean (95% CI) change in weight (kg) from baseline to one, two, and three month follow-up in
abstinent untreated smokers. For the Shiffman studies, smokers were stratified and received two different treatments on
the basis of nicotine dependence level (separated in “a” and “b” groups). For the Fiore studies, “a” and “b” refer to two
separate studies reported in the same article
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Fig 3 Meta-analyses of mean (95% CI) change in weight (kg) from baseline to six and 12 month follow-up in abstinent
untreated smokers. For the Shiffman studies, smokers were stratified and received two different treatments on the basis
of nicotine dependence level (separated in “a” and “b” groups)
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Fig 4 Meta-analyses of mean (95% CI) change in weight (kg) from baseline to one, two, and three month follow-up in
abstinent smokers treated with nicotine replacement therapy (any dose, any regimen). For the Shiffman studies, smokers
were stratified and received two different treatments on the basis of nicotine dependence level (separated in “a” and “b”
groups). For the Fiore studies, “a” and “b” refer to two separate studies reported in the same article
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Fig 5 Meta-analyses of mean (95% CI) change n weight (kg) from baseline to six and 12 month follow-up in abstinent
smokers treated with nicotine replacement therapy (any dose, any regimen). For the Shiffman studies, smokers were
stratified and received two different treatments on the basis of nicotine dependence level (separated in “a” and “b” groups)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e4439 doi: 10.1136/bmj.e4439 (Published 10 July 2012) Page 18 of 21
RESEARCH
Fig 6 Meta-analyses of mean (95% CI) change in weight (kg) from baseline to two, three, six, and 12 month follow-up in
abstinent smokers treated with bupropion (300 mg/day)
Fig 7Meta-analyses of mean (95%CI) change in weight (kg) from baseline to two, three, and 12 month follow-up in abstinent
smokers treated with varenicline (2 mg/day)
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Fig 8 Percentage of untreated quitting population who would be expected to lose weight, gain <5 kg, gain 5-10 kg, or gain
>10 kg over 12 months
Fig 9 Percentage of quitting population treated with nicotine replacement therapy who would be expected to lose weight,
gain <5 kg, gain 5-10 kg, or gain >10 kg over 12 months
Fig 10 Percentage of quitting population treated with bupropion who would be expected to lose weight, gain <5 kg, gain
5-10 kg, or gain >10 kg over 12 months
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Fig 11 Percentage of quitting population treated with varenicline who would be expected to lose weight, gain <5 kg, gain
5-10 kg, or gain >10 kg over 12 months
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